BLA 125104 · Biogen Idec
Tysabri
Natalizumab · Single-Use · Integrin Receptor Antagonist
NovelAccelerated approvalPriority reviewLast checked: Nov 20, 2026Latest source record: Mar 18, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Nov 23, 2004
Approved uses
6
Original approval plus efficacy supplements
Registered trials
75
17 Phase 3, 6 recruiting
FAERS reports
181,255
56,644 serious, 5,131 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability. Risk factors for the development of PML include the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants. These factors should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI [ see Warnings and Precautions ( 5.1 ) ]. Healthcare professionals should monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML. TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML. For diagnosis, an evaluation that includes a gadolinium-enhanced magnetic resonance imaging (MRI) scan of the brain and, when indicated,...
What it is approved for
From the label in effect Oct 9, 2026.
TYSABRI is an integrin receptor antagonist indicated for treatment of: Multiple Sclerosis (MS) TYSABRI is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. TYSABRI increases the risk of PML [See Warnings and Precautions ( 5.1 ) ]. When initiating and continuing treatment with TYSABRI, physicians should consider whether the expected benefit of TYSABRI is sufficient to offset this risk. ( 1.1 ) Crohn's Disease (CD) TYSABRI is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-α. ( 1.2 ) Important Limitations: In CD, TYSABRI should not be used in combination with immunosuppressants or inhibitors of TNF-α. ( 1.2 ) 1.1 Multiple Sclerosis (MS) TYSABRI is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. TYSABRI increases the risk of PML [ see Warnings and Precautions ( 5.1 ) ]. When initiating and continuing treatment with TYSABRI, physicians should consider whether the expected benefit of TYSABRI is sufficient to offset this risk. 1.2 Crohn's Disease (CD) TYSABRI is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and...
Mechanism: Natalizumab binds to the α4-subunit of α4β1 and α4β7 integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the α4-mediated adhesion of leukocytes to their counter-receptor(s). The receptors for the α4 family of integrins include vascular cell adhesion molecule-1 (VCAM-1), which is expressed on activated vascular endothelium, and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) present on vascular endothelial cells of the gastrointestinal tract. Disruption of these molecular interactions prevents transmigration of leukocytes across the endothelium into...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 15, 2013 Supplement 840 · Efficacy LabelLetter
- Jan 20, 2012 Supplement 576 · Efficacy LabelLetter
- Oct 3, 2008 Supplement 67 · Efficacy LabelLetter
- Jan 14, 2008 Supplement 33 · Efficacy LabelLetterReview
- Jun 5, 2006 Supplement 15 · Efficacy · priority review LabelSummary ReviewLetter
- Nov 23, 2004 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalLetterLabelReview
1 products under this application
- TYSABRI · NATALIZUMAB 300MG · VIAL, SINGLE-USE · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Natalizumab" as an intervention, any sponsor and status, largest first.
BiogenBiogen (BIIB)
NCT00280956 · 2,000 participants (planned) · Start Jul 2002 · Primary completion Sep 2004
Drug: natalizumab · For: Crohn's Disease
Sites: San Diego, California
- Open-Label Natalizumab Safety Extension StudyPivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT00276172 · 1,615 participants · Start Dec 2003 · Primary completion Oct 2005
Drug: Natalizumab · For: Multiple Sclerosis
Sites: Cambridge, Massachusetts
- Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple SclerosisPivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT00030966 · 1,200 participants · Start Jan 2002 · Primary completion Apr 2005
Drug: Natalizumab; Placebo · For: Multiple Sclerosis, Relapsing-Remitting
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 88 sites in all
- Natalizumab (Tysabri) Re-Initiation of DosingPivotal-lookingTerminated
BiogenBiogen (BIIB)
NCT00297232 · 1,094 participants · Start Mar 2006 · Primary completion Apr 2014
Drug: Natalizumab · For: Relapsing-Remitting Multiple Sclerosis
Sites: Camperdown, Australia; Heidelberg, Australia; Parkville, Australia · 112 sites in all
- Safety and Efficacy of Natalizumab in the Treatment of Crohn's DiseasePivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT00032799 · 905 participants · Start Dec 2001 · Primary completion Sep 2003
Drug: natalizumab · For: Crohn's Disease
Sites: San Diego, California
- Safety and Efficacy of Natalizumab in the Treatment of Multiple SclerosisPivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT00027300 · 900 participants · Start Nov 2001 · Primary completion Nov 2004
Drug: Natalizumab; Placebo · For: Multiple Sclerosis, Relapsing-Remitting
Sites: Scottsdale, Arizona; Berkeley, California; Davis, California · 53 sites in all
- A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple SclerosisPivotal-lookingTerminated
BiogenBiogen (BIIB)
NCT01416181 · 889 participants · Start Sep 13, 2011 · Primary completion Jul 28, 2015
Drug: natalizumab; Placebo · For: Secondary Progressive Multiple Sclerosis
Sites: Phoenix, Arizona; Tucson, Arizona; Fullerton, California · 161 sites in all
- Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMSPivotal-lookingActive, not recruiting
The Cleveland ClinicAcademic, hospital or other
NCT03535298 · 800 participants (planned) · Start Jan 3, 2019 · Primary completion Jul 30, 2027
Drug: Early Highly Effective Therapies Group; Escalation Therapies Group · For: Multiple Sclerosis, Relapsing-Remitting
Sites: Aurora, Colorado; Minneapolis, Minnesota; Rochester, Minnesota · 30 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue19,632
- multiple sclerosis relapse16,953
- headache10,010
- multiple sclerosis9,821
- gait disturbance9,507
- fall8,050
- asthenia8,012
- memory impairment7,972
- malaise7,449
- drug ineffective6,917
- urinary tract infection6,323
- pain5,988
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 1,355 |
| 2006 | 48 |
| 2007 | 559 |
| 2008 | 1,549 |
| 2009 | 2,555 |
| 2010 | 20,069 |
| 2011 | 25,662 |
| 2012 | 22,980 |
| 2013 | 29,497 |
| 2014 | 12,502 |
| 2015 | 7,069 |
| 2016 | 8,948 |
| 2017 | 8,570 |
| 2018 | 8,295 |
| 2019 | 6,205 |
| 2020 | 5,145 |
| 2021 | 3,964 |
| 2022 | 4,362 |
| 2023 | 3,971 |
| 2024 | 3,274 |
| 2025 | 2,831 |
| 2026 | 1,843 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tysabri (Natalizumab)
2024 spending
$37.2M
Beneficiaries
566
4,470 claims
Per beneficiary
$65,659
$565.71 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $41,553,342 |
| 2021 | $43,445,960 |
| 2022 | $45,770,526 |
| 2023 | $40,471,107 |
| 2024 | $37,162,951 |
Part B: Tysabri (Natalizumab) · HCPCS J2323
2024 spending
$159M
Beneficiaries
2,778
22,673 claims
Per beneficiary
$57,169
2024 ASP limit $24.23 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $217,864,711 |
| 2021 | $208,017,215 |
| 2022 | $204,974,045 |
| 2023 | $184,186,605 |
| 2024 | $158,815,402 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis.
Samjoo IA, Drudge C, Walsh S, et al. · J Comp Eff Res 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Gonzalez-Lorenzo M, Ridley B, Minozzi S, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials.
Ben-Horin S, Novack L, Mao R, et al. · Gastroenterology 2022 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis.
Rindi LV, Zaçe D, Braccialarghe N, et al. · Drug Saf 2024 · Systematic Review, Meta-Analysis
- Multiple sclerosis.
Nicholas R, Rashid W · BMJ Clin Evid 2012 · Systematic Review
- Multiple sclerosis.
Nicholas R, Chataway J · BMJ Clin Evid 2009 · Systematic Review
Sponsor: Biogen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.